Singapore, June 3 -- MarkHerz Inc., a South Korea-based biotechnology startup specialising in AAV-based gene therapies targeting cardiovascular and metabolic diseases, has signed a Memorandum of Understanding (MoU) withKlinikum rechts der Isar, the university hospital affiliated with theTechnical University of Munich(TUM), Germany.

The agreement aims to establish a broad-based collaboration on the joint research and development of next-generation gene therapies for ischemic heart and peripheral vascular diseases.

This will center around MarkHerz's proprietaryMAAV Platform, which enables the development of precision-targeted AAV (adeno associated virus) gene therapies, particularly its MRTF-A candidate. The collaboration will include pre...